ALA-3000, a monthly release injectable of Ketamine, indicating for treatment-resistant depression (TRD). Through the controlled release formulation, it is anticipated that the steady pharmacokinetic profile would reduce the risks of adverse events resulting from ketamine (e.g. dissociation, sedation, and perceptual changes) and improve patient compliance.